Antibiotics may help treat common form of dementia: Study


Team Udayavani, Jan 11, 2020, 4:16 PM IST

Washington: Researchers have found that a class of antibiotics called ‘aminoglycosides’ may be a promising treatment for a form of early onset dementia, an advance that may lead to new clinical strategies against the memory decline syndrome.

According to the study, published in the journal Human Molecular Genetics, frontotemporal dementia, the most common type of the syndrome, begins between ages 40 and 65, and affects the frontal and temporal lobes of the brain.

The syndrome leads to behaviour changes, difficulty in speaking, writing, and memory deterioration, the researchers, including those from the University of Kentucky in the US, said.

Some patients with this form of dementia have a specific genetic mutation which prevents their brain’s cells from making a protein called progranulin, the scientists said in a statement.

While the protein is not thoroughly studied, researchers believe that its absence is linked to this form of dementia.

In the current study, scientists discovered that after aminoglycoside antibiotics were added to nerve cells exhibiting this mutation, the cells started making full-length progranulin protein by skipping the mutation.

“These patients’ brain cells have a mutation that prevents progranulin from being made. The team found that by adding a small antibiotic molecule to the cells, they could ‘trick’ the cellular machinery into making it,” said Matthew Gentry, a co-author of the study from the University of Kentucky.

Two aminoglycoside antibiotics – Gentamicin and G418 – were both effective in fixing the mutation, and making the functional progranulin protein, the study noted.

According to the researchers, adding Gentamicin or G418 molecules to the affected cells, caused them to produce the protein at levels of up to 50 to 60 per cent as produced by normal cells without the mutation.

The scientists plan to study the antibiotics’ effects on mice carrying the mutation which causes frontotemporal dementia.

While Gentamicin is a clinically approved medicine, the researchers said its usage is limited since it is associated with a number of adverse side effects.

“If we can get the right resources and physician to work with, we could potentially repurpose this drug. This is an early stage of the study, but it provides an important proof of concept that these aminoglycoside antibiotics or their derivatives can be a therapeutic avenue for frontotemporal dementia,” said study co-author Haining Zhu from the University of Kentucky.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Ullal: Auto-rickshaw accident near Konaje claims driver’s life

Congress victory in bypolls not a clean chit to CM in MUDA case: R Ashoka

IPL 2025 | Got someone who can do captaincy job: Ricky Ponting on Shreyas Iyer

Bad timing: Fraudsters call senior Indore cop during press briefing to pull off ‘digital arrest’

Kangana says MVA lost in Maharashtra because it disrespected women

UP: Protest over Sambhal mosque survey turns violent; 3 killed, 20 cops among injured

Ranbir Kapoor says he would love to remake grandfather Raj Kapoor’s ‘Shree 420’

Related Articles More

Mangaluru: Campco opposes WHO’s claim of arecanut being carcinogenic

10 month baby gets new heart, new life

World COPD Day: Know your lung function

As Delhi chokes with dangerous pollution levels, doctors warn of health risks for all

World Diabetes Day 2024: Kasturba Hospital Manipal Hosts Zumba Session at Malpe Beach to Raise Diabetes Awareness

MUST WATCH

Coconut Flower

Prakash Belawadi

Naxal Leader Vikram Gowda

Christmas Cake Fruit Mixing

DK Shivakumar


Latest Additions

No one has right to break law: BJP on Sambhal violence

Ullal: Auto-rickshaw accident near Konaje claims driver’s life

Congress victory in bypolls not a clean chit to CM in MUDA case: R Ashoka

IPL 2025 | Got someone who can do captaincy job: Ricky Ponting on Shreyas Iyer

Will review INDI alliance’s dismal performance in Maharashtra, says Tejashwi Yadav

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.